Navigating the labyrinth of American healthcare costs has long been a source of profound confusion and anxiety for consumers, often leaving them in the dark about the true price of care until a bill arrives. In a direct response to this persistent challenge, the Trump administration has proposed a
Today, we're speaking with James Maitland, an expert in healthcare innovation and the intricate dynamics between the pharmaceutical industry, government policy, and financial markets. We'll be exploring the recent wave of drug pricing deals between major pharmaceutical companies and the White
The long-promised transformation of American healthcare from a system that pays for the quantity of services to one that rewards the quality of patient outcomes is reaching a pivotal and defining moment. This ongoing, critical shift away from the traditional fee-for-service model is more than a
With the Department of Health and Human Services signaling a major push to accelerate artificial intelligence in healthcare, the industry is at a critical juncture. The agency's recent Request for Information (RFI) isn't just a survey; it's an invitation to co-author the future of clinical care. To
The U.S. Food and Drug Administration (FDA) finds itself navigating a complex and fractured landscape as it endeavors to craft a regulatory framework for the real-world performance of medical devices driven by artificial intelligence (AI) and machine learning (ML). Following a call for public
With the administration proposing new rules that could fundamentally alter the landscape of healthcare for transgender youth, we are joined by James Maitland, a leading expert in U.S. healthcare policy and regulation. These proposals aim to restrict gender-affirming care by threatening to cut
